[National guidelines of diagnosis and treatment of the non-Hodgkin lymphoma]

Non-Hodgkin lymphoma comprises a heterogeneous group of haematological malignancies, classified according to their clinic, anatomic-pathological features and, lately, to their molecular biomarkers. Despite the therapeutic advances, nearly half of the patients will die because of this disease. The new diagnostic tools have been the cornerstone to design recent therapy targets, which must be included in the current treatment guidelines of this sort of neoplasms by means of clinical trials and evidence-based medicine. In the face of poor diagnoses devices in most of the Mexican hospitals, we recommend the present diagnose stratification, and treatment guidelines for non-Hodgkin lymphoma, based on evidence. They include the latest and most innovative therapeutic approaches, as well as specific recommendations for hospitals with limited framework and therapy resources.

[Lymphoma. Current status and treatment]

The use of single-cell polymerize chain reaction analysis has allowed for a better understanding of the origin of Hodgkin's disease, Burkitt. The study of the mechanisms regulating apoptosis and the survival of neoplastic clones have opened a whole area of research. The Revised European-American List of lymphoid neoplasms must be presented in a form that facilitates the understanding, learning, and teaching of these disorders. There is a great need for a better definition of the new category of lymphoplasmacytic lymphoma, the variants of mantle cell lymphoma and marginal zone B-cell lymphomas, and the coming of age of the NK-cell lymphomas. Based on current data, it is difficult to determine the site of transplantation in the management of follicular, low-grade non-Hodgkin's lymphoma. These patients remain at risk of relapse after transplantation, mirroring results with conventional therapy. The treatment of aggressive lymphomas remains an area of significant controversy. The Intergroup Study concluded that none of the more recent regimens was superior to CHOP. Recent data suggest that high-dose therapy with consolidative autologous or allogenic transplant may benefit patients with aggressive histology lymphoma who have poor prognostic features.